

## DAFTAR PUSTAKA

1. World Health Organization. Novel Coronavirus (2019-nCoV) SITUATION REPORT - 1. Vol. 10, Materials and Methods. 2020.
2. Sahin AR. 2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature. *Eurasian J Med Oncol*. 2020;4(1):1–7.
3. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology*. 2018;23(2):130–7.
4. Yan-Rong G et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. *Mil Med Res*. 2020;7(11):1–10.
5. Worldometers. COVID-19 as of 25 November 2020 [Internet]. Worldometers. 2020. Available from: <https://www.worldometers.info/coronavirus/>
6. ASEAN Biodiaspora Virtual Center. Risk assessment for international dissemination of COVID-19 to the ASEAN region. Vol. 2020. 2020.
7. World Health Organization. WHO Indonesia Situation Report - 35. Vol. 19, World Health Organization. 2020.
8. Kominfo Sumbar. Info Covid-19 Sumbar, Rabu 25 November 2020 [Internet]. 2020. Available from: <https://sumbarprov.go.id/home/news/19840-info-covid-19-sumbar-rabu-25-november-2020.html>
9. Satuan Tugas Penanganan Covid-19. Gugus Tugas Percepatan Penanganan Gugus Tugas Percepatan Penanganan COVID-19 [Internet]. 2020. Available from: <https://covid19.go.id/>
10. Irwan. Buku Epidemiologi Penyakit Menular. Vol. 1, CV. Absolute Media. 2017. 107 p.
11. Hidayani WR. Faktor Faktor Risiko Yang Berhubungan Dengan COVID 19 : Literature Review. *J Untuk Masyarakat Sehat*. 2020;4(2):120–34.
12. Alam MR, Kabir MR, Reza S. Comorbidities might be a risk factor for the incidence of COVID-19: Evidence from a web-based survey. *Prev Med Reports*. 2021;21:101319.
13. Hernández-gardu E. Obesity is the comorbidity more strongly associated for Covid-19 in Mexico, A case-control study. *Elsevier*. 2020;14(January):375–9.
14. Odegaard JI, Chawla A. Connecting type 1 and type 2 diabetes through innate immunity. *Cold Spring Harb Perspect Med*. 2012;
15. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. *The Lancet Infectious Diseases*. 2009.
16. Babapoor-Farrokhran S, Gill D, Walker J. Myocardial injury and COVID-19: Possible mechanisms. *Life Sci*. 2020;253(April):117723.
17. Shahbazi F, Khazaei S. Socio-economic inequality in global incidence and mortality rates from coronavirus disease 2019: an ecological study. *New Microbes New Infect*. 2020;
18. Baker MG, Peckham TK, Seixas NS. Estimating the burden of United States workers exposed to infection or disease: A key factor in containing risk of COVID-19 infection. *PLoS One*. 2020;
19. Shahbazi F, Solgi M, Khazaei S. Predisposing risk factors for COVID-19 infection: A case-control study. *Casp J Intern Med*. 2020;11(Suppl 1):495.
20. Kementerian Kesehatan RI. PEDOMAN PENCEGAHAN DAN PENGENDALIAN CORONAVIRUS DISEASE (COVID-19). Departemen

- Kesehatan Republik Indonesia. 2020. 1–214 p.
21. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708–20.
  22. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727–33.
  23. Satuan Tugas Penanganan COVID-19. ANALISIS DATA COVID-19 INDONESIA Per 29 November 2020. 2020.
  24. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res*. 2020;24:91–8.
  25. Liu T, Hu J, Xiao J, He G, Kang M, Rong Z, et al. Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China. *BioRxiv*. 2020;
  26. Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19). Treasure Island (FL): StatPearls Publishing; 2021.
  27. Kenneth McIntosh. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, and prevention. *Lancet Infect Dis*. 2020;1:1–31.
  28. Neeltje van Doremalen P, Infectious (National Institute of Allergy and, Diseases), Trenton Bushmaker BSNI of A and, Diseases), Dylan H. Morris MP (Princeton U. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med*. 2020;0–2.
  29. De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. *Nat Rev Microbiol*. 2016;14(8):523–34.
  30. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. *J Med Virol*. 2020;92(4):424–32.
  31. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. *J Penyakit Dalam Indones*. 2020;7(1):45.
  32. Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese N, et al. Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review. *Int J Environ Res Public Health*. 2020;17(8).
  33. Lingeswaran M, Goyal T, Ghosh R, Suri S, Mitra P, Misra S, et al. Inflammation, Immunity and Immunogenetics in COVID-19: A Narrative Review. *Indian J Clin Biochem*. 2020;35(3):260–73.
  34. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. World Health Organization. 2020;
  35. Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. *Clin Gastroenterol Hepatol*. 2020;18(9):2128.
  36. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol*. 2020;17(5):259–60.
  37. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol*. 2020;5(5):428–30.
  38. Manssor B, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. *Lancet Gastroenterol Hepatol*. 2020;5(6):529.
  39. Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, et al. Patients of COVID-19 may

- benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. *Int J Infect Dis.* 2020;95:183–91.
40. Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability. *Lancet Glob Heal.* 2020;8(4):e480.
  41. Bao L, Deng W, Gao H, et al. Lack of Reinfection in 1 Rhesus Macaques Infected with SARS-CoV-2. *BioRxiv.* 2020;21(1):1–9.
  42. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR Test Results in Patients Recovered from COVID-19. *JAMA - J Am Med Assoc.* 2020;323(15):1502–3.
  43. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chin Med J (Engl).* 2020;133(9):1039–43.
  44. Prabandari, Fitria, Purwoko. Hubungan antara Skor Kerapuhan dengan Lama Rawat Pasien Lanjut Usia : Studi pada Bangsal Rawat Inap Geriatri RSUP Dr. Kariadi Semarang. Vol. 53, Diponegoro University. 2017.
  45. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;
  46. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J Am Med Assoc.* 2020;
  47. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol.* 2004;
  48. Carstensen J, Andersson D, André M, Engström S, Magnusson H, Borgquist LA. How does comorbidity influence healthcare costs? A population-based cross-sectional study of depression, back pain and osteoarthritis. *BMJ Open.* 2012;
  49. Sarfati D, Gurney J, Lim BT, Bagheri N, Simpson A, Koea J, et al. Identifying important comorbidity among cancer populations using administrative data: Prevalence and impact on survival. *Asia Pac J Clin Oncol.* 2016;
  50. Wang A, Zhao W, Xu Z, Gu J. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. *Diabetes Res Clin Pract.* 2020;162:108118.
  51. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. *Diabetes Res Clin Pract.* 2020;162:108142.
  52. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. *BMJ Open Diabetes Res Care.* 2020;8(1):1–9.
  53. Elissa D, Mahees V M, Behnood B, Taylor C, Justin L, Giuseppe B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. *J Am Coll Cardiol.* 2020;75(18):2352-2371h.
  54. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *The Lancet Respiratory Medicine.* 2020.
  55. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. *Am J Hypertens.* 2020;33(5):373–8.

56. BOZKURT B, KOVACS R, HARRINGTON B. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 BIYKEM. *J Card Fail.* 2020;26(5):19–20.
57. Qiu H, Tong Z, Ma P, Hu M, Peng Z, Wu W, et al. Intensive care during the coronavirus epidemic. *Intensive Care Medicine.* 2020.
58. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol.* 2020;
59. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PAB, Bartlett NW, et al. Role of deficient type III interferon- $\lambda$  production in asthma exacerbations. *Nat Med.* 2006;
60. Sun J, Zhu A, Li H, Zheng K, Zhuang Z, Chen Z, et al. Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. *Emerging Microbes and Infections.* 2020.
61. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney International.* 2020.
62. Nuswantari. *Kamus Kedokteran Dorland.* 25th ed. Jakarta: EGC; 1998.
63. Depkes RI. *Klasifikasi Umur Menurut Kategori.* 2009.
64. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA - Journal of the American Medical Association.* 2020.
65. Murray MA, Chotirmall SH. The Impact of Immunosenescence on Pulmonary Disease. *Mediators of Inflammation.* 2015.
66. Gitlin AD, Nussenzweig MC. Immunology: Fifty years of B lymphocytes. *Nature.* 2015;
67. Pritz T, Lair J, Ban M, Keller M, Weinberger B, Krismer M, et al. Plasma cell numbers decrease in bone marrow of old patients. *Eur J Immunol.* 2015;
68. Momon S. *Sosiologi Untuk Kesehatan.* Jakarta: Salemba Medika; 2008. 188 p.
69. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature.* 2020;
70. KBBI. *Kamus Besar Bahasa Indonesia [Internet].* KBBI. Available from: <https://kbbi.kemdikbud.go.id/entri/pekerjaan>
71. Kementerian Tenaga Kerja. UU No. 13 Tahun 2003 tentang Ketenagakerjaan. Kementerian Tenaga Kerja Jakarta; 2003.
72. Qun L, Xuhua G, Peng W, Xiaoye W, Lei Z, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *N Engl J Med.* 2020;382(13):1199–207.
73. Sim MR. The COVID-19 pandemic: Major risks to healthcare and other workers on the front line. *Occupational and Environmental Medicine.* 2020.
74. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages — The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic. *N Engl J Med.* 2020;
75. S.J. B, K. B, W. L, K.D. M, M.S. E, S.S. S. Smoking upregulates angiotensin-converting Enzyme-2 receptor: A potential adhesion site for novel coronavirus SARS-CoV-2 (COVID-19). *J Clin Med.* 2020;

76. Listyoko AS, Djajalaksana S, Astuti T. Hubungan Merokok Dengan Derajat Keparahan Dan Mortalitas Pasien COVID-19 Rawat Inap di RS Saiful Anwar Malang. *J Clin Med*. 2020;7(1A):137–43.
77. CDC. Interim U.S. Guidance for Risk Assessment and Work Restrictions for Healthcare Personnel with Potential Exposure to COVID-19. CDC. 2020;
78. Chen B, Liang H, Yuan X, Hu Y, Xu M, Zhao Y, et al. Roles of meteorological conditions in COVID-19 transmission on a worldwide scale. *medRxiv*. 2020;
79. Sajadi MM, Habibzadeh P, Vintzileos A, Shokouhi S, Miralles-Wilhelm F, Amoroso A. Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and Seasonality of Coronavirus Disease 2019 (COVID-19). *JAMA Netw open*. 2020;3(6):e2011834.
80. Ratnesar-Shumate S, Williams G, Green B, Krause M, Holland B, Wood S, et al. Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces. *J Infect Dis*. 2020;222(2):214–22.
81. Chin AWH, Poon LLM. Stability of SARS-CoV-2 in different environmental conditions – Authors’ reply. *The Lancet Microbe*. 2020;1(4):e146.
82. Desai D. Urban densities and the Covid-19 pandemic: Upending the sustainability myth of global megacities. Vol. 244, Observer Research Foundation. 2020. 1–38 p.
83. Zaytsev P, Hasaneini SJ, Ruina A. *Pr ep rin t Pr ep t*. 2015;
84. Carrat F, Touvier M, Severi G, Meyer L, Jusot F, Lapidus N, et al. Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study. *BMC Infect Dis*. 2021;21(1):1–13.
85. Dinas Kesehatan Pesisir Selatan. Profil Kesehatan Tahun 2019 Kab. Pessel. Dinas Kesehatan Pesisir Selatan. 2019.
86. Magdalena, Sugiri YJ, Tantular R, Listyoko A. KARAKTERISTIK KLINIS PASIEN COVID-19 DI RUMAH SAKIT DR. SAIFUL ANWAR, MALANG. *J Respirologi Indones*. 2021;41(1).
87. Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, et al. Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: A nationwide case-control study. *J Korean Med Sci*. 2020;35(25):1–15.
88. Kishore J, Bharti A, Heena, Yadav G, Gupta N, Meena R. Risk Factors of COVID-19 among Patients Attending a Tertiary Care Centre in Delhi: A Case Control Study. *Epidemiol Int*. 2020;05(04):5–11.
89. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. *J Community Empower Heal*. 2020;3(2):77.
90. Sun Y, Koh V, Marimuthu K, Ng OT, Young B, Vasoo S, et al. Epidemiological and clinical predictors of COVID-19. *Clin Infect Dis*. 2020;71(15):786–92.
91. Hobbs C V, Martin LM, Kim SS, Kirmse BM, Haynie L, Mcgraw S, et al. Factors Associated with Positive SARS-CoV-2 Test Results in Outpatient Health Facilities and Emergency Departments Among Children and Adolescents Aged < 18 Years — Mississippi , September – November 2020. Vol. 69, *Morbidity and Mortality Weekly Repor*. 2020. p. 1925.
92. Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 Transmission from People without COVID-19 Symptoms. *JAMA Netw Open*. 2021;4(1):4–11.

93. Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, Sadran M, et al. Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. *Emerg Infect Dis.* 2016;
94. Cunningham A. COVID-19 kills more men than women. The immune system may be why. *Science News.* 2020.
95. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. *Biology of Sex Differences.* 2020.
96. Koh D. Occupational risks for COVID-19 infection. *Occupational Medicine.* 2020.
97. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. *Lancet Infect Dis.* 2020;20(9):238–44.

